| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_12f1c8a7a19bf041112bca3ec41618ba |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S530-80
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S530-806 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-275
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4702
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-275
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44 |
| filingDate |
1990-11-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
1993-03-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f3f506369dca3257dd8430959019cc4a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3b1ffd178e19ee3220866a6eb6a2ea96
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b3cb9df317751e0f611cd882028ce3cf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c3d6f881791981832daa416919c7009d |
| publicationDate |
1993-03-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-5192664-A |
| titleOfInvention |
Parathyroid hypertensive factor, antibodies and uses thereof |
| abstract |
PCT No. PCT/US90/01577 Sec. 371 Date Nov. 21, 1990 Sec. 102(e) Date Nov. 21, 1990 PCT Filed Nov. 21, 1990 PCT Pub. No. WO90/11074 PCT Pub. Date Oct. 4, 1990.A new circulating factor from the parathyroid gland of some hypertensive mammals have been isolated and characterized. Polyclonal and monoclonal antibodies raised against this factor are usable as a screen for the presence of the factor. The factor is involved in the control of calcium uptake in cells. Hypertensive mammals may be treated to lower mean blood pressure by administering a calcium channel blocking agent together with one or both of a calcium supplement and Vitamin D. The hypotensive effect of this combination is synergistic and the dose response is more predictable than the administration of any of these agents singly. The factor has a molecular weight of 3,000 to 4,000 Daltons. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008069814-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009069276-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9902548-A1 |
| priorityDate |
1989-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |